KISSEI PHARMACEUTICAL CO.,LTD.
4547 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 松本市芳野１９番４８号
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
KISSEI PHARMACEUTICAL CO., LTD. is a Japanese pharmaceutical company dedicated to advancing health through innovative treatments. Established with a commitment to research and development, Kissei focuses on creating therapies for various medical conditions, including chronic diseases. The company recently announced the launch of TAVALISSE® for the treatment of Chronic Idiopathic Thrombocytopenic Purpura in South Korea, reflecting its ongoing dedication to addressing unmet medical needs. Kissei's strategic vision is outlined in its medium-term management plan, "Beyond 80," aimed at fostering sustainable growth and enhancing shareholder value. With a robust R&D pipeline, Kissei is poised to contribute significantly to the future of healthcare.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-27 06:00 |
Inside Information Statement
臨時報告書
|
Japanese | 23.3 KB | |
| 2025-06-24 06:01 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2025-06-24 06:01 |
Internal Control over Financial Reporting
内部統制報告書－第80期(2024/04/01－2025/03/31)
|
Japanese | 25.5 KB | |
| 2025-06-24 06:00 |
Annual Report
有価証券報告書－第80期(2024/04/01－2025/03/31)
|
Japanese | 1.5 MB | |
| 2025-06-11 06:00 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 22.6 KB | |
| 2024-12-27 08:00 |
Major Shareholding Notification
大量保有報告書
|
Japanese | 38.5 KB | |
| 2024-12-13 05:00 |
Transaction in Own Shares
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
|
Japanese | 24.9 KB | |
| 2024-11-13 05:01 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-11-13 05:00 |
Interim Report
半期報告書－第80期(2024/04/01－2025/03/31)
|
Japanese | 240.5 KB | |
| 2024-06-28 06:00 |
Inside Information Statement
臨時報告書
|
Japanese | 29.4 KB | |
| 2024-06-25 06:01 |
Internal Control over Financial Reporting
内部統制報告書－第79期(2023/04/01－2024/03/31)
|
Japanese | 23.8 KB | |
| 2024-06-25 06:00 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-06-25 06:00 |
Annual Report
有価証券報告書－第79期(2023/04/01－2024/03/31)
|
Japanese | 1.5 MB | |
| 2024-02-13 05:00 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-02-13 05:00 |
Quarterly Report
四半期報告書－第79期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 193.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |